Gilead Sciences, Inc.: Gilead Presents Long-Term Switch Data Reinforcing Biktarvy as a Treatment Option for a Broad Range of People Living With HIV
- Analysis of Real-World Data in People Living With HIV in the International BICSTaR Study to be Presented at EACS 2021 Also Confirm the Long-Term Efficacy and Safety Profile of Biktarvy - Gilead
Source: finanznachrichten.de